Haley Laken, Ph.D. is a drug development strategy expert encompassing target identification through product approval. She is currently COO of Tabby Therapeutics, a company focusing on the broader applications of B cell technology in therapeutics and drug discovery, enabling healthcare professionals to treat diseases. Prior to that, she was the Senior Vice President of Program and Portfolio Strategy and Management Team member at Jounce Therapeutics, a publicly traded immunotherapy company with three assets advancing through clinical development. Dr. Laken established the immunotherapy pipeline at TESARO, moving three novel antibody candidates into the clinic in 18 months and leading to the pending approval of PD-1 inhibitor dostarlimab. She was also instrumental in the development of the program leadership and management function at TESARO during a period of rapid growth and transition to a commercial stage company. Dr. Laken has held positions of increasing strategic drug development leadership at Rhythm Pharmaceuticals, Pfizer, and Wyeth and contributed to the development of BESPONSAR and IMCIVREETM during her tenure at Wyeth and Rhythm respectively.

Dr. Laken received her Ph.D. in human genetics and molecular biology from Johns Hopkins University and a B.A. in biology from DePauw University.